Author | Sandra J. Horning, MD

Articles

Hodgkin Lymphoma in Older Patients: An Uncommon Disease in Need of Study

November 15, 2008

ByAndrew M. Evens, DO, MS|John W. Sweetenham, MD|Sandra J. Horning, MD

Hodgkin lymphoma (HL) is one of the most curable malignancies in adults. However, survival rates for elderly patients with HL (often defined as ≥ 60 years of age) are inferior to those achieved by younger populations.

Indolent B-Cell Non-Hodgkin’s Lymphomas

December 01, 1997

ByDavid S. Morgan, MD|Sandra J. Horning, MD

B-cell non-Hodgkin’s lymphomas (NHL) are an increasingly common cause of cancer morbidity and mortality. In 1996, approximately 52,700 new cases of NHL were diagnosed, representing a marked increase in incidence. Indeed, the incidence rose from 8.5 per 100,000 population in 1973 to 15.1 per 100,000 in 1992.[1] About 20% to 30% of these are NHLs of the indolent varieties.

Hodgkin's Disease: Management of First Relapse

February 01, 1996

ByAlan R. Yuen, MD|Sandra J. Horning, MD

In most patients with newly diagnosed Hodgkin's disease, initial therapy is curative. However, a small portion of patients treated with radiotherapy alone for limited favorable disease, and a larger percentage of patients treated with combination chemotherapy, with or without radiotherapy, for advanced-stage or unfavorable disease relapse after initial remission. Patients relapsing after radiotherapy alone should do as well with salvage combination chemotherapy as patients with advanced disease who have never received radiation. In patients who relapse after combination chemotherapy, retreatment with the same regimen or employment of a non-cross-resistant regimen offers high response rates among those with favorable characteristics.